ID
45473
Description
Principal Investigator: Laura Pasqualucci, MD, Institute for Cancer Genetics, Columbia University, New York, NY, USA MeSH: Lymphoma, Non-Hodgkin,Lymphoma, B-Cell https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000502 Splenic Marginal Zone Lymphoma (SMZL) is a B-cell malignancy of unknown pathogenesis and thus orphan of targeted therapies. By integrating whole-exome sequencing and copy-number analysis of 8 paired tumor-normal DNAs from patients with SMZL, we show that the typical SMZL exome carries ~30 genetic alterations. Targeted resequencing of selected candidates in an extended panel of 40-117 samples revealed activating mutations of NOTCH2, a gene required for marginal-zone (MZ) development, as the most frequent and SMZL-specific lesion, accounting for approximately 20% of cases. Additional altered genes suggest that deregulation of signaling pathways normally involved in MZ development (NOTCH, NF-kappa B, and B-cell receptor) represents a critical event in SMZL pathogenesis. These findings have direct implications for the treatment of SMZL patients since drugs are available which can target NOTCH as well as other pathways deregulated in this disease.
Lien
Mots-clés
Versions (2)
- 31/10/2022 31/10/2022 - Tabea Kampen
- 13/12/2022 13/12/2022 - Kristina Keller
Détendeur de droits
Laura Pasqualucci, MD, Institute for Cancer Genetics, Columbia University, New York, NY, USA
Téléchargé le
13 décembre 2022
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
dbGaP phs000502 Genome-Wide Analysis of Splenic Marginal Zone Lymphoma
Sample ID, analyte type, tumor status, body site where sample was collected, and histological diagnosis of tumors obtained from participants with splenic marginal zone lymphoma and involved in the "Genome-Wide Analysis of Splenic Marginal Zone Lymphoma" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants with splenic marginal zone lymphoma and involved in the "Genome-Wide Analysis of Splenic Marginal Zone Lymphoma" project.
- Sample ID, subject ID and sample use variables obtained from participants with splenic marginal zone lymphoma and involved in the "Genome-Wide Analysis of Splenic Marginal Zone Lymphoma" project.
- Sample ID, analyte type, tumor status, body site where sample was collected, and histological diagnosis of tumors obtained from participants with splenic marginal zone lymphoma and involved in the "Genome-Wide Analysis of Splenic Marginal Zone Lymphoma" project.
Similar models
Sample ID, analyte type, tumor status, body site where sample was collected, and histological diagnosis of tumors obtained from participants with splenic marginal zone lymphoma and involved in the "Genome-Wide Analysis of Splenic Marginal Zone Lymphoma" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants with splenic marginal zone lymphoma and involved in the "Genome-Wide Analysis of Splenic Marginal Zone Lymphoma" project.
- Sample ID, subject ID and sample use variables obtained from participants with splenic marginal zone lymphoma and involved in the "Genome-Wide Analysis of Splenic Marginal Zone Lymphoma" project.
- Sample ID, analyte type, tumor status, body site where sample was collected, and histological diagnosis of tumors obtained from participants with splenic marginal zone lymphoma and involved in the "Genome-Wide Analysis of Splenic Marginal Zone Lymphoma" project.
C0012854 (UMLS CUI [1,2])
C0027651 (UMLS CUI [2,1])
C0012854 (UMLS CUI [2,2])
C0520510 (UMLS CUI [1,2])
C0040300 (UMLS CUI [2,1])
C0200345 (UMLS CUI [2,2])
C0205307 (UMLS CUI [1,2])
C0012854 (UMLS CUI [1,3])
Aucun commentaire